Anti Cd 20 Ocrevus denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Issues Duplicate-Therapy Denials for Ocrelizumab

Cigna may deny ocrelizumab (Ocrevus) as "duplicate therapy" when its utilization-management system detects that the patient is already receiving — or has recently received — another therapy that Cigna categorizes as treating the same condition through a comparable mechanism. In practice, this most often arises when a patient is transitioning from another anti-CD20 agent, when there is an overlap in authorization periods, or when a second MS medication is being added as part of a clinician-directed management change. The denial label is misleading: it does not mean the drug is wrong for the patient, only that Cigna's system flagged a potential overlap that requires clinical explanation.

## Why This Denial Is Appealable

A duplicate-therapy denial is an adverse benefit determination. Under ACA §2719 and ERISA §503 you have the right to a full-and-fair internal appeal and, if upheld, independent external review by a certified IRO. The external-review window is generally around four months from the adverse determination; verify your plan's exact deadline. Expedited review is available when delay poses a serious health risk.

## Your Appeal Timeline

1. Request the denial letter and Cigna's duplicate-therapy criteria — identify exactly which therapy or claim Cigna considers duplicative. 2. Clarify the clinical situation with the prescriber: is this a transition (old therapy stopping, new one starting), a correction of a billing overlap, or an intentional combination? 3. File the internal appeal with a letter explaining why the two therapies are not clinically duplicative for this patient. 4. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Current medication list with dates: a clear timeline showing which MS therapy is being discontinued and when, and when ocrelizumab is intended to begin — eliminating any apparent overlap.
• Prescriber transition letter: the neurologist should explain the therapeutic rationale for the switch, the planned washout or transition period (if any), and why the two agents are not being used concurrently as equivalent treatments.
• Prior therapy records: evidence that the "duplicate" drug is being or has been discontinued — prescription stop dates, infusion records, or pharmacy fill history.
• Diagnosis and clinical context: current neurology notes establishing why ocrelizumab is the appropriate next therapy for this patient's specific disease state.
• FDA prescribing label for ocrelizumab: confirm the approved indication and, if transitioning from another anti-CD20 agent, note any label guidance on transitions.

## Criteria-Mapping Structure

Obtain Cigna's published duplicate-therapy or clinical coverage policy for ocrelizumab and map the key facts:

| Cigna Duplicate-Therapy Concern | Clinical Reality for This Patient | Supporting Document | |---|---|---| | Concurrent use of [other agent] | [Other agent] discontinued on [date] | Prescription record / infusion log | | Same-mechanism overlap | Transition is sequential, not concurrent | Prescriber transition letter | | Medical necessity of switch | Disease activity / inadequate response | Neurology note, [Date] |

A clear timeline and a direct prescriber explanation are the two most effective tools for resolving a duplicate-therapy denial.